These 2 Dividend Stocks Are Absolute Bargains Right Now

Group 1: AbbVie - AbbVie has faced challenges, including the loss of patent exclusivity for its top-selling drug, Humira, leading to a significant drop in revenue and share price in early 2023 [2] - Despite setbacks, AbbVie's revenue for 2024 increased by 3.7% to $56.3 billion, and adjusted earnings per share decreased by 9$10.12, partly due to acquisition-related expenses [4] - AbbVie is recognized as a Dividend King with 52 consecutive years of dividend increases and offers a forward yield of about 3.7%, making it attractive for income investors [5] Group 2: Gilead Sciences - Gilead Sciences' shares have increased by almost 29% over the trailing-12-month period, with a forward P/E of 12.9 indicating it may be undervalued [6] - The company's revenue for the first nine months of 2024 rose by 6% year over year to $21.2 billion, while adjusted EPS was$2.72, down almost 46% compared to the previous year due to acquisition-related charges [6][7] - Gilead has made significant progress in its pipeline, focusing on various therapeutic areas, including HIV and oncology, and has increased its dividend by about 79% over the past 10 years, with a forward yield of approximately 3.1% [8][9]